Publicaciones en colaboración con investigadores/as de Hospital de Mataró (14)

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care

  2. HIV/HBV coinfection: Temporal trends and patient characteristics, Spain, 2002 to 2018

    Eurosurveillance, Vol. 26, Núm. 25

  3. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Critical Care, Vol. 25, Núm. 1

2020

  1. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

2018

  1. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

  2. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2012

  1. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study

    BMC Infectious Diseases, Vol. 12

2010

  1. Inhaled drugs as risk factors for communityacquired pneumonia

    European Respiratory Journal, Vol. 36, Núm. 5, pp. 1080-1087

2008

  1. New evidence of risk factors for community-acquired pneumonia: A population-based study

    European Respiratory Journal, Vol. 31, Núm. 6, pp. 1274-1284

2007

  1. Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain

    Medicina Clinica